Revenue increased 29% to $13.5 million in Q3 2025 as compared with Q3 2024 Operating income totaled $1.3 million and Adjusted EBITDA rose approximately 80% to $2.0 million in Q3 2025, as compared with Q3 2024 Remaining performance obligations increased to $65 million FDA cleared an accelerated protocol for Deep TMS treatment of patients with major depressive disorder (MDD) Raised midpoint of full-year 2025 Revenue and EBITDA guidance Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 11, 2025 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported third quarter 2025 financial results and provided an operational update. Recent Financial and...

VANCOUVER, British Columbia, Nov. 11, 2025 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology business solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS and Quantum Computing solutions, announces financial results for the third quarter ended September 30, 2025, which includes a record 1,225% increase in year-over-year revenue for the quarter. The company achieved a 6X revenue increase for the first nine months of the year with revenue of $7.73 million compared to the same period of 2024 (all figures are in Canadian dollars). These results represent the company’s highest-ever quarterly revenue driven by exceptional performance of the Drone as a Service segment and in addition includes the highest ever quarterly...

Palvella’s recently expanded rare disease pipeline now comprises QTORIN™-derived product candidates advancing in four serious, rare skin diseases that currently have no FDA-approved therapies Top-line results for fully enrolled Phase 2 TOIVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for cutaneous venous malformations remain on track for mid-December 2025 Top-line results for fully enrolled Phase 3 SELVA trial evaluating QTORIN™ rapamycin for microcystic lymphatic malformations remain on track for the first quarter of 2026 Expanded QTORIN™ rapamycin’s development into clinically significant angiokeratomas, a rare and debilitating lymphatic disease with no FDA-approved therapies, with Phase 2 study initiation anticipated in second half of 2026 Announced new QTORIN™...

Conference call will be held today, Tuesday, November 11 at 9:00 am ET CARMEL, Ind., Nov. 11, 2025 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the third quarter period ended September 30, 2025. 3Q25 Financial highlightsRevenues increased 22% year over year to $811 thousand in 3Q25 compared to $667 thousand in 3Q24. Operating loss in 3Q25 increased 27% year over year compared to 3Q24 due to increased sales and marketing efforts. Cash balance was $4.4 million as of September 30, 2025. Subsequently, the Company secured an additional $2.8 million through an at-the-market equity offering and warrant exercises in October 2025.Recent...

MONTREAL, Nov. 11, 2025 (GLOBE NEWSWIRE) — Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) (“Aya” or the “Corporation”) today announced third quarter financial and operational results for the three-month period ended September 30, 2025. All amounts are in US dollars, unless otherwise stated. Q3-2025 Highlights OperationalRecord silver production of 1.35 million (“M”) ounces (“oz”) up 278% vs. the prior year driven by the new Zgounder plant; and up 29% increase quarter-over-quarter (“QoQ”), driven by record throughput and improved grades. Ore processed averaged 3,326 tonnes per day (tpd), up 11% QoQ, with high mill availability of 96%. Mill average feed grade of 146 grams per tonne (“g/t”) Ag, showing improvement QoQ driven by higher-grade underground ore. Silver recovery averaged 92.5% in Q3-2025.FinancialRecord...

Advances Strategic Transformation with Key Changes in Executive Leadership, Product Development and Operations ROMEOVILLE, Ill., Nov. 11, 2025 (GLOBE NEWSWIRE) — Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the third quarter ended September 30, 2025. Recent Highlights and AccomplishmentsContinued strategic transformation to drive future innovation and growth with promotion of Kevin Cureton to President and Chief Executive Officer. Appointed Laura Riffner, a seasoned financial and operations expert, as Chief Financial Officer to lead accounting and finance management and support strategic planning. Yoana Dvorzsak to lead newly unified group that combines Solésence’s research and development, product and component...

Please find enclosed Eika Boligkreditt AS’ interimreport for the third quarter 2025. The report is also available on http://eikbol.no/AttachmentEika Boligkreditt AS – Report 3Q 2025

Quarterly net revenues were RMB795.4 million (US$111.7 million)1Quarterly lidar shipments were 441,398 unitsQuarterly net income was RMB256.2 million (US$36.0 million) SHANGHAI, China, Nov. 11, 2025 (GLOBE NEWSWIRE) — Hesai Group (“Hesai” or the “Company”) (NASDAQ: HSAI; HKEX: 2525), the global leader in three-dimensional light detection and ranging (lidar) solutions, today announced its unaudited financial results for the three months ended September 30, 2025. Management Remarks “We’re thrilled to report another stellar quarter — hitting our full-year net income target a quarter ahead of schedule! We’ve also maintained our leadership in long-range automotive lidar for seven straight months, capturing an impressive 46% market share in August — 1.5 times the second player and 2.4 times the third, according to Gasgoo,” said Dr. Yifan...

Zug, 11 November 2025 – Multitude AG, a listed European FinTech company, offering digital lending and online banking services to consumers, small and medium-sized enterprises, and other FinTechs (WKN: A40VJN, ISIN: CH1398992755) (“Multitude”, “Company” or “Group”) warmly invites financial analysts, investors, and media to its combined 9M Financial Results Earnings Call and Capital Markets Day 2025 webcast. The event will be held virtually on Thursday, 13 November 2025, starting with the 9M 2025 Financial Results Earnings Call at 13:00 CET. The Capital Markets Day presentation will commence at 13:45 CET.    A link for registration to the webcast of the event is available on the company website in the subsection financial calendar https://www.multitude.com/investors/financial-calendar. Contact:Multitude AG Grafenauweg 8  6300 Zug Switzerland Adam...

Interim Management Statement covering Q1 2025/26 The Board of Directors of Rovsing A/S has today reviewed and approved the Interim Management Statement for the first quarter (1 July 2025– 30 September 2025) of the financial year 2025/26. Q1 highlights: Revenue and EBITDA trailing expectations due to increased project efforts – Solid Order Backlog and Rising Tender ActivityIn the first quarter of the financial year 2025/26, revenue and EBITDA came in below expectations, primarily due to increased efforts required to complete ongoing projects compared to the original budgets. A significant part of this relates to a large project expected to be completed during the current financial year. In addition, a service-based project has been temporarily delayed pending input from the customer and is expected to resume later in the financial year.Revenue...